Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
ACS Chem Biol. 2010 May 21;5(5):489-97. doi: 10.1021/cb100011u.
Human N-acetyl-beta-hexosaminidase (Hex) isozymes are considered to be important targets for drug discovery. They are directly linked to osteoarthritis because Hex is the predominant glycosidase released by chondrocytes to degrade glycosaminoglycan. Hex is also associated with lysosomal storage disorders. We report the discovery of GlcNAc-type iminocyclitiols as potent and selective Hex inhibitors, likely contributed by the gain of extra electrostatic and hydrophobic interactions. The most potent inhibitor had a K(i) of 0.69 nM against human Hex B and was 2.5 x 10(5) times more selective for Hex B than for a similar human enzyme O-GlcNAcase. These glycosidase inhibitors were shown to modulate intracellular levels of glycolipids, including ganglioside-GM2 and asialoganglioside-GM2.
人 N-乙酰-β-己糖苷酶(Hex)同工酶被认为是药物发现的重要靶点。它们与骨关节炎直接相关,因为 Hex 是软骨细胞释放的主要糖苷酶,可降解糖胺聚糖。Hex 还与溶酶体贮积症有关。我们报告了 GlcNAc 型亚氨基环糖醇作为潜在的、选择性的 Hex 抑制剂的发现,这可能归因于额外的静电和疏水相互作用的获得。最有效的抑制剂对人 Hex B 的 K(i)为 0.69 nM,对 Hex B 的选择性比类似的人酶 O-GlcNAcase 高 2.5 x 10(5)倍。这些糖苷酶抑制剂被证明可以调节细胞内糖脂的水平,包括神经节苷脂-GM2 和唾液酸神经节苷脂-GM2。